2021 YEAR-END NEWSLETTER
We are pleased to report that PhorMed has raised over $1,900,000. We have over 3,400 investors and over 7,890 followers, which has doubled and nearly tripled our numbers respectively from the same time last year. In May we relaunched our Regulation CF campaign with the goal of raising a maximum of $5 million. We are now 38 percent of the way to that goal.
Being a start-up company, we have been relying on your assistance in funding our clinical research and the expansion of our intellectual property by way of new discoveries, and we want to extend our appreciation and inform you, the investor, how we are utilizing our capital through strategic hires, clinical research and expansion of intellectual property, our pipeline.
We have once again retained the services of Jeffrey King. He specializes in biotechnology patent procurement and related services, with a focus on chemistry, rational drug design, molecular biology, immunology, vaccine development and related clinical technologies. Mr. King has considerable experience helping to build life sciences start-up companies into industry market leaders and working with universities and public research institutions to help protect and partner their technology assets with business. He received his B.S. in Zoology from University of Washington, his M.S. in Biology from University of Victoria, is a Ph.D. candidate in Molecular Biology at Indiana University, Bloomington and received his J.D. from University of Washington School of Law. His work in patent writing, clinical study design, and grant writing are key elements to our future success and we are grateful for this collaboration.
Sean O’Connell was a new hire in 2021 and our Chief Medical Officer. Sean is responsible for study design, protocol writing, and reviewing all correspondence and filings between the FDA, clinical sites and Contract Research Organizations (CRO). Sean will represent the company at speaking engagements when it relates to our technology. We are pleased to have Sean with us moving into 2022 as our pipeline continues to grow and through the continuing advancements of our technology.
EXPANDING OUR TECHNOLOGY
Through our research and clinical trials we have discovered a new use for our primary compound RP-323. Mr. King is working on writing a new patent application for this discovery and we will announce this once the application is completed and accepted by the USPTO.
Mr. King is currently hard at work on a Grant application to further our COVID-19 research. We will release relevant updates on this process as they become available.
UPDATES BY INDICATION
AML – A ‘go-ahead’ has been given by the FDA to enter into a Phase II study with an abbreviated Phase I or Phase I/II. We made the decision to amend the approved protocol to allow us to use a higher dose than the previously discovered Maximum Tolerated Dose (MTD) for our Phase 1B study. This amendment is under review at our collaborating partner, Winship Cancer institute at Emory University and once it is completed, we will go back to the FDA for their review.
Hodgkin’s Lymphoma – The study protocol has been completed and we are waiting on the response from the FDA in regards to the maximum tolerated dose for the AML study, which will determine if the Hodgkin’s protocol will also need the same type of amendment. We will file this application once we determine the best path to take.
COVID-19/ARDS – We are actively engaged in the ARDS pre-clinical studies looking for efficacy utilizing the research facilities at Absorption Systems, Inc. (ASI). We are currently in pre-clinical stages for COVID-19 studies but moving forward we will request that we move directly into Phase II bypassing Phase I, since we already have a safety profile for RP-323 that has been reviewed and accepted as safe by the FDA. We will also apply for fast-track status*.
Parkinson’s disease – As previously announced, we are in a collaboration with Emory University and working with their team to determine the best course of action, study design, determine priority end-points and continue with safety studies. Concurrently, we are working with ASI and are in discussions with a second lab on extending pre-clinical trials to find additional markers, end-points and added safety. For these studies we will also be requesting to bypass Phase I, similar to our COVID-19 studies.
*All of our studies have the possibilities of Fast-Track due to the lack of current treatments and options. We have or will be applying for these designations for each of our indications.
We want to sincerely thank you for investing with PhorMed and being part of our vision. As we get closer to our current funding goal, we would like to again ask that you both consider investing further in our technology, and sharing this opportunity with anyone you know who may be interested and is like-minded in their desire to join us on this journey.
Thank you for being part of the PhorMed family. I wish you and yours good health, and a happy and successful 2022.
Ben Chang, CEO
The information contained within was obtained from Company and public information. The contents of this communication do not constitute an offer of securities or a solicitation of an offer to buy securities and may not be relied upon in making an investment decision related to any investment offering by Company, or any affiliate, or partner thereof ("Issuer"). These investment opportunities have not been registered under the Securities Act of 1933 and are being offered pursuant to an exemption therefrom and from applicable state securities laws. Past performance is no guarantee of future results. All information is subject to change. You should always consult a tax professional prior to investing. The Company, its shareholders, and Advisor make no representations or warranties, express or implied, as to the accuracy or completeness of the information contained in this communication and nothing herein is or shall be relied upon as, a representation or warranty with respect to past or future facts or results.